Biogen Idec stellt auf der 30. Annual J.P. Morgan Healthcare Conference …Business Wire (Pressemitteilung)Weitere Fortentwicklung des Programms Phase 3 mit Daclizumab bei MS. Bildung von Wissenschaftlerteams von Weltklasse in den therapeutischen Kernb…
This Month in Archives of NeurologyArchives of NeurologyGorman et al (SEE ARTICLE) report the use of daclizumab in pediatric-onset multiple sclerosis (POMS). They find that daclizumab may be a safe and at least partially effective treatment option for …
Biogen Idec présente ses priorités stratégiques pour 2012 lors de la 30ème …TF1… qui auront tous deux des données publiées cette année. poursuivant le développement du programme de phase 3 du daclizumab pour la SP. renforçant les collabora…
Biogen Idec presenta le priorità strategiche per il 2012 in occasione della …ANSA.it… lancio ea richieste normative successivi. realizzazione del programma di fase 3 per il daclizumab nella SM. approfondimento delle collaborazioni strategiche esis…
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan …MarketWatch (press release)Continuing to advance the daclizumab Phase 3 program in MS. — Drive innovation and grow early-stage pipeline by: — Building world-class scientific…
ECTRIMS/ACTRIMS, Teil 2: Experimentelle MS-Therapien in der PipelineDMSG Multiple Sklerose NachrichtenDaclizumab – Die Phase II SELECT Studie untersuchte monatliche, unter die Haut verabreichte Injektionen eine niedrigen (150mg) und einer hohen (300m…
Abbott Labs Spinoff Looks Like the Right MoveInvestorplace.comAlso in development is daclizumab, which appears to be both safe and effective in treating the most common form of multiple sclerosis. Phase III testing is also underway for bardoxolone, whi…
Ricerca per Alzheimer, schizofrenia e sclerosi multiplaANSA.itNel dettaglio, si tratta di "Daclizumab", molecola sviluppata in partnership con Biogen, in fase tre di sviluppo per il trattamento della sclerosi multipla recidivante-remittente, …
Nature.comSuccess of immunomodulators in MS shifts discovery focus to neuroprotectionNature.comThe other Phase III candidates include Sanofi's oral dihydroorotate dehydrogenase inhibitor teriflunomide, Roche/Biogen Idec's injectable CD20-specif…
MedPage TodayClinical Context – Multiple SclerosisMedPage TodayTreatment with the monoclonal antibody daclizumab (Zenapax) resulted in significant decreases in contrast-enhancing lesions on MRI in patients with multiple sclerosis (MS), a small, open-…